文献速递血管炎

巨细胞动脉炎诊断前后静脉血栓栓塞风险的时间趋势

Temporal Trends of Venous Thromboembolism Risk Before and After Diagnosis of Giant Cell Arteritis.
PubMed 文献 · Arthritis Rheumatol · 2017-01-01

基于英国电子病历数据库的匹配队列研究显示,巨细胞动脉炎(GCA)患者诊断前12个月内静脉血栓栓塞(VTE)风险已升高,诊断时达峰值,后逐渐下降;未用糖皮质激素的 imminent GCA 患者风险仍升高,提示炎症相关血栓独立于激素使用。

要点

  • GCA诊断前12个月VTE风险已升高,诊断时达峰值,随后逐渐下降。
  • 未用口服糖皮质激素的 imminent GCA 患者诊断前VTE风险仍升高。
  • 提示炎症相关血栓形成独立于糖皮质激素使用。

核心结论

  • GCA患者VTE风险在诊断前不久开始升高,诊断时达峰值,之后逐渐下降;该风险在未暴露于口服糖皮质激素的 imminent GCA 患者中仍可见,提示炎症相关血栓独立于激素使用。

研究设计与样本

  • 匹配队列研究,使用代表英国人群的电子病历数据库(1990-2013),比较6,441例新发GCA患者与63,985例对照。
  • 计算年龄、性别和入组时间匹配及多变量相对风险(RR),诊断前分析按口服糖皮质激素使用分层。

主要发现

  • GCA诊断前12个月内发生27例VTE事件,诊断后发生195例。
  • 诊断前12、9、6、3个月,未用糖皮质激素的 imminent GCA 患者年龄、性别和入组时间匹配的VTE RR分别为1.8、2.2、2.4、3.6。
  • 诊断后3、6、12、24、48、96个月,相应RR分别为9.9、7.7、5.9、4.4、3.3、2.4。
  • 包括多个常见VTE危险因素的多变量分析显示相似趋势。

关键数值与推荐

  • 诊断前12、9、6、3个月未用糖皮质激素的 imminent GCA 患者VTE的RR分别为1.8、2.2、2.4、3.6。
  • 诊断后3、6、12、24、48、96个月VTE的RR分别为9.9、7.7、5.9、4.4、3.3、2.4。

临床怎么用

  • 临床应关注GCA患者诊断前后的VTE风险,尤其诊断时风险最高。
  • 即使未使用糖皮质激素,疑似GCA患者仍应警惕VTE可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Giant cell arteritis (GCA) and the use of glucocorticoids have both been associated with increased risk of venous thromboembolism (VTE). However, the possibility of confounding by indication has not been investigated. We undertook this study to examine the temporal risk of VTE in GCA patients before and after GCA diagnosis, accounting for confounders including glucocorticoid treatment. METHODS: We conducted a matched cohort study using an electronic medical record database representative of the UK population (1990-2013). We calculated age-, sex-, and entry time-matched and multivariate relative risks (RRs) of VTE, comparing 6,441 patients with new-onset GCA (defined by corresponding diagnosis codes and prescribed glucocorticoid treatment) to 63,985 controls before and after GCA diagnosis. Analysis before GCA diagnosis was stratified by oral glucocorticoid use to account for confounding. RESULTS: There were 27 incident VTE events during the 12 months preceding GCA diagnosis and 195 afterward. Compared to controls, during the 12, 9, 6, and 3 months preceding GCA diagnosis, the age-, sex-, and entry time-matched RRs for VTE among patients with imminent GCA not treated with glucocorticoids were 1.8, 2.2, 2.4, and 3.6, respectively. In the first 3, 6, 12, 24, 48, and 96 months after GCA diagnosis, the corresponding RRs were 9.9, 7.7, 5.9, 4.4, 3.3, and 2.4. Multivariate analyses including several common VTE risk factors showed similar trends. CONCLUSION: The risk of VTE increases shortly before GCA diagnosis, peaks at the time of diagnosis, and then progressively declines thereafter. This risk is apparent in patients with imminent GCA unexposed to oral glucocorticoids, suggesting a role for inflammation-associated thrombosis that is independent of glucocorticoid use.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Unizony S, Lu N, Tomasson G, et al. Temporal Trends of Venous Thromboembolism Risk Before and After Diagnosis of Giant Cell Arteritis. Arthritis Rheumatol. 2017. PMID: 28029234. doi:10.1002/art.39847

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。